Rapid Onset of Effect of Benralizumab on Morning Peak Expiratory Flow in Severe, Uncontrolled Asthma

Benralizumab (Fasenra™) is an interleukin (IL)-5 receptor alpha–directed cytolytic monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils in the circulation.1 Benralizumab is approved for use in Canada, Europe, Japan, and the United States.2–5 In the United States, it is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.2 In the SIROCCO (NCT01928771) and CALIMA (NCT01914757) Phase III clinical trials, benralizumab treatment significantly reduced asthma exacerbations, increased lung function, and improved asthma symptoms in patients with severe, uncontrolled asthma and baseline blood eosinophil counts ≥300 cells/μL.

https://ift.tt/2Ergbln